Oncopremium Team S.R.L.

The site focuses on small-cell lung cancer research, evaluating new therapeutic combinations to improve patient survival.

• Immunotherapy plus chemotherapy regimens
• Lurbinectedin as single agent or with Irinotecan
• Management of relapsed disease after platinum failure
• Assessment of overall survival outcomes

Oncopremium Team S.R.L. conducts these trials in Baia Mare, aiming to advance treatment options for this aggressive cancer.

Studies target first‑line treatment of extensive-stage small-cell lung cancer, comparing novel immune‑checkpoint inhibitors with standard chemotherapy.

• Pembrolizumab combined with chemotherapy
• Progression‑free survival as a primary endpoint
• Enrollment based on PD‑L1 CPS ≥1
• Blinded independent central radiologic review

The research seeks to establish more effective first‑line regimens for patients who have not received prior chemotherapy.

Clinical work at the center includes trials for HR+/HER2‑ negative breast cancer, testing immunotherapy added to chemotherapy in patients without prior cytotoxic treatment.

• Pembrolizumab plus chemotherapy versus placebo plus chemotherapy
• Evaluation of overall survival benefit
• Biomarker‑driven patient selection
• Focus on non‑curative disease setting

The oncology department leverages its expertise to improve outcomes for breast cancer patients across Romania.